论文部分内容阅读
3例重症肝病合并感染患者(均为男性,年龄分别为40、68、50岁)接受碳青霉烯类、利奈唑胺及氟康唑联合治疗,期间未出现明显血象变化。因疗效不佳换用哌拉西林钠他唑巴坦钠4.5 g,8 h/次静脉滴注。其中例1于换用哌拉西林钠他唑巴坦钠11 d后出现贫血及血小板计数下降;例2、例3分别于换用哌拉西林钠他唑巴坦钠4、7 d后出现贫血加重及血小板计数下降。3例患者分别在停用哌拉西林钠他唑巴坦钠后31、21、7 d,血红蛋白及血小板计数明显恢复。
Three patients with severe liver disease (both male, age 40, 58, and 50 years) with carbapenem, linezolid and fluconazole, respectively, had no significant changes in blood. Due to poor efficacy in exchange for piperacillin sodium tazobactam sodium 4.5 g, 8 h / sub-intravenous infusion. In Example 1, the results showed that anemia and platelet count decreased after switching to piperacillin and tazobactam for 11 days. In cases 2 and 3, anemia occurred after 4 and 7 days of piperacillin and tazobactam Increased and decreased platelet count. Three patients were stopped piperacillin sodium tazobactam sodium 31,21,7 d, hemoglobin and platelet count was significantly restored.